Orchard Therapeutics
101 Seaport Boulevard, 7th Floor
Boston
MA
02210
United States
Website: http://www.orchard-tx.com/
Email: careers@orchard-tx.com
About Orchard Therapeutics
At Orchard Therapeutics, our vision is to end the devastation caused by genetic and other severe diseases. We aim to do this by discovering, developing and commercializing new treatments that tap into the curative potential of HSC gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease in a single treatment.
In 2018, the company acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Today, Orchard has a deep pipeline spanning pre-clinical, clinical and commercial stage HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.
Orchard has its global headquarters in London and U.S. headquarters in Boston.
Company Ownership: Public
Stock Symbol: ORTX
Stock Exchange: NASDAQ
157 articles with Orchard Therapeutics
-
Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress
5/12/2022
Orchard Therapeutics, a global gene therapy leader, announced recent business highlights along with its financial results for the quarter ended March 31, 2022.
-
Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond
5/10/2022
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined seven presentations from across its platform to be featured at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting taking place May 16-19 in Washington, D.C.
-
Orchard Therapeutics to Webcast Conference Call of First Quarter 2022 Financial Results
5/5/2022
Orchard Therapeutics announced that the company will host a conference call and live webcast on Thursday, May 12, 2022, at 8:00 a.m. ET to review business updates and its first quarter 2022 financial results.
-
Orchard Therapeutics Announces Agreement Enabling Access and Reimbursement for Libmeldy for All Eligible MLD Patients in Germany
5/2/2022
Orchard Therapeutics today announced it has reached an agreement with Gesetzliche Krankenversicherung Spitzenverband (GKV-SV) which will result in reimbursed access to Libmeldy ® (atidarsagene autotemcel) for all metachromatic leukodystrophy (MLD) patients in Germany who fall within the scope of the European marketing authorization.
-
Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy
4/11/2022
Orchard Therapeutics, a global gene therapy leader, announced it has reached another historic reimbursement agreement with the Italian Medicines Agency, also known as Agenzia Italiana del Farmaco, to enable access to Libmeldy® for all children with metachromatic leukodystrophy who fall within the scope of the European marketing authorization.
-
Several employees at three biopharma firms are not having a very good week, as Zealand Pharma, Merck and Orchard Therapeutics all announced job cuts.
-
Orchard Therapeutics Extends Runway into 2024, Focusing HSC Gene Therapy Platform Exclusively on Severe Neurometabolic Diseases and Research Platform
3/30/2022
Orchard Therapeutics today announced its intention to focus its hematopoietic stem cell (HSC) gene therapy platform exclusively on severe neurometabolic diseases and early research programs while also reporting its financial results for the quarter and year ended December 31, 2021.
-
Orchard Therapeutics announced today that it intends to focus its hematopoietic stem cell (HSC) gene therapy platform exclusively on severe neurometabolic diseases and early research programs.
-
Orchard Therapeutics to Webcast Conference Call of Fourth Quarter and Fiscal Year 2021 Financial Results
3/24/2022
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Wednesday, March 30, 2022, at 8:00 a.m. ET to review business updates and its fourth quarter and fiscal year 2021 financial results.
-
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2022
3/3/2022
Orchard Therapeutics, a global gene therapy leader, announced that members of the management team will present at the following investor conferences.
-
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
-
Orchard Therapeutics Announces Multiple Presentations at WORLDSymposium™ 2022
2/7/2022
Orchard Therapeutics, a global gene therapy leader, outlined five upcoming presentations from across its neurodegenerative portfolio to be featured at the 18th Annual WORLDSymposium™ being held on February 7-11, 2022.
-
Orchard Therapeutics Announces Historic Agreement Making Libmeldy Available by NHS England for MLD Patients
2/3/2022
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with the National Health Service (NHS) that enables access to Libmeldy® (atidarsagene autotemcel) for all children with metachromatic leukodystrophy (MLD) in England and Wales who fall within the scope of the European marketing authorization.
-
Orchard Therapeutics Announces Publication in The Lancet of Long-term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-onset MLD
1/21/2022
Orchard Therapeutics today announced the publication in The Lancet of long-term clinical outcomes evaluating the safety and efficacy of Libmeldy® (atidarsagene autotemcel) for the treatment of early-onset metachromatic leukodystrophy (MLD).
-
Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones
1/10/2022
Orchard Therapeutics, a global gene therapy leader, outlined commercial and regulatory updates and key 2022 milestones in advance of its attendance at the virtual 40th Annual J.P. Morgan Healthcare Conference.
-
Orchard Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday January 13, 2022, at 9:00 a.m. ET.
-
Clinical Catch-Up: November 15-19
11/22/2021
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look. -
Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome
11/18/2021
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced data published in the New England Journal of Medicine (NEJM) evaluating the safety and efficacy of OTL-203 for the treatment of the Hurler subtype of Mucopolysaccharidosis type I (MPS-IH).
-
Orchard Therapeutics to Present at Virtual Investor Conferences in November 2021
11/8/2021
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present and be available for one-on-one meetings at the following virtual investor conferences.
-
Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates
11/4/2021
Orchard Therapeutics today reported financial results for the quarter ended September 30, 2021, as well as recent business updates and upcoming milestones.